Cybin Inc

ASE:CYBN   4:00:00 PM EDT
6.01
-0.08 (-1.31%)
4:23:59 PM EDT: $6.02 +0.01 (+0.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Cybin Inc Stock, ASE:CYBN

100 King Street West, Suite 5600, Toronto, Ontario M5X 1C9
Phone: +1.908.764.8385
Number of Employees:

Description

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.